Abstract: An agricultural baler includes: a frame; a bale chamber coupled with the frame; and a control system including: at least one sensor coupled with the frame, positioned circumferentially relative to the bale chamber, and configured for sensing an operative parameter of a crop material in the bale chamber.

Abstract: The present invention relates generally to a method for the treatment or prophylaxis of a condition which provokes, or is exacerbated by, an immunological response. The present invention further enables methods of diagnosis of conditions which provoke, or are exacerbated by, an immunological response. The present invention further provides therapeutic and diagnostic agents for conditions which provoke, or are exacerbated by, an immunological response. The present invention further provides compositions of cells defining a sub-population of CD4+ T cells defined by CMRF-35 and CD45RO.

Abstract: The inventors have identified intergenically spliced DEC-205/DCL-1 mRNAs, which encode the intact DEC-205 ectodomain together with an additional carbohydrate recognition domain, a transmembrane domain and a cytoplasmic domain derived from DCL-1. These DEC-205/DCL-1 intergenic splice variants were identified on Reed-Sternberg cells and thus have application in the therapy and investigation of Hodgkin's disease.

Abstract: The present invention relates generally to therapeutic and diagnostic agents. More particularly, the present invention provides molecules having structural features characteristic of immunoregulatory signaling (IRS) molecules and which are expressed by cells of heaematopoietic lineages such as, in particular, leukocytes. The molecules of the present invention find broad application inter alia as diagnostic markers for cells, targets for cell therapy and as validated drug targets in order to modulate the immune response and to treat, prevent and diagnose a range of diseases conditions including cancer, genetic disease, inflammatory conditions and conditions associated with aberrant haematopoietic cell function or activity. The present invention extends to binding partners of the instant molecules such as, for example, antibodies, ligands, adaptor and other signaling associated molecules, agonists and antagonists and to methods of screening for same.

Abstract: The present invention relates generally to a method for modulating the immuno-activity of an antigen-presenting cell and agents useful therefor. More particularly, the present invention relates to a method for preventing or down-regulating one or more functional activities of a dendritic cell. The present invention further provides antibodies and, in particular, monoclonal antibodies, which interact specifically with epitopes present on the surface of dendritic cells, resulting in depletion, down-regulation or destruction of targeted dendritic cell in vivo or in vitro. The instant invention further provides a method for modulating an immune response in a subject and, in particular, for down-regulating the immuno-activity of an allogeneic immuno-competent graft and/or the immune response of a recipient of a solid organ transplant.

Abstract: The present invention relates generally to a method for modulating the activity of cells of the immune system, including stimulator and responder cells and to agents useful therefor. More particularly, the present invention relates to a method for preventing or down-regulating one or more functional activities of stimulator and responder cells such as, respectively, antigen-presenting cells and lymphocytes inter alia. The present invention further provides antibodies, which interact specifically with epitopes present on the surface of antigen-presenting cells and lymphocytes, resulting in depletion, down-regulation or destruction of targeted antigen-presenting cells and lymphocytes in vivo or in vitro. The instant invention further provides a method for modulating an immune response in a subject and, in particular, for down-regulating the immuno-activity of an allogeneic immuno-competent graft and/or the immune response of a recipient of a solid organ transplant.

Abstract: A method of characterizing cells in a subclass of dendritic cells or precursors thereof in a biological sample. The method comprising placing the sample in contact with immunointeractive molecules directed to at least one dendritic cell immunogen (e.g. HLA-DR, CE123, CD11c, CD1b/c, BDCA2, BDCA3, BDCA4, Cb16, CD83, CD45, CD40, CMRF-44 AND CMRF-56) and CMRF-56) and at least one non-dendritic cell immunogen (e.g. CD3, CD19, CD14, CD56, CD11b, CD34) and detecting the presence of one or more dendritic cell immunogen-immunointeractive molecule complexes and the absence of one or more non-dendritic cell immunogen-immunointeractive molecule complexes. An analysis of the cells of the subclass of dendritic cells is performed based on the presence and absence of the above complexes. This method may be used in disease diagnosis by comparing the number of cells in the subset of dendritic cells or precursors thereof with the number of the same subset of cells found in an age-matched non-diseased patient.

Abstract: The present invention relates to an isolated domain of G3BP-2 that mediates binding between G3BP-2 and other proteins, and nucleic acids encoding same. The invention also relates to a method for diagnosing, treating and preventing breast cancer including the step of using a nucleic acid and/or encoded polypeptide for G3BP-2, or fragment thereof, to detect, treat or prevent breast cancer in a mammal, preferably human. In one particular form, the invention relates to an antigen presenting cell, preferably a dendritic cell, that is capable of presenting G3BP-2 or fragments thereof. The invention also relates to lymphocytes, in particular cytotoxic T-lymphocytes, that are G3BP-2 antigen specific.

Abstract: The present invention relates to a method for inducing development of dendritic cells from CD34+ precursor cells. More particularly, the present invention relates to a method of differentiating CD34+ precursor cells into myeloid- and or lymphoid-dendritic cells. The present invention provides a protocol for the development of dendritic cells from a biological sample inter alia cord blood, bone marrow or peripheral blood CD34+ stem cells. The dendritic cells of the present invention are useful as therapeutic cellular agents such as in the development of vaccines and in modulating immunological responsiveness. More particularly, the present invention provides compositions which can be used for inducing a protective immune response in a subject against inter alia pathogenic infections, autoimmune diseases and cancer.

Abstract: Enzyme having AHCY-type activity and DNA sequences which encode the enzyme. The enzyme is useful in a screening assay to identify compounds useful as immunosuppression agents.

Abstract: The invention provides isolated human DEC-205, its extracellular domain and functionally equivalent fragments thereof. Also provided are polynucleotides encoding same and vectors which include such polynucleotides. Further provided are methods of recombinantly producing human DEC-205, an extracellular domain thereof or a functionally equivalent fragment, and ligands that bind to human DEC-205 or a fragment thereof. Also provided are constructs for use in prophylaxis or therapy comprising such a ligand, human DEC-205 or an extracellular domain thereof coupled to a toxin or to an antigen capable of inducing a protective immune response in a patient.

Abstract: The present invention relates generally to a method of modulating the immunoactivity of a population of immune cells and, more particularly to a method of down-regulating the immunoactivity of an immunocompetent graft. The method of the present invention is useful, inter alia, in the treatment and/or prophylaxis of conditions characterised by aberrant, unwanted or otherwise inappropriate graft immunoactivity such as, but not limited to, the prophylaxis treatment of graft versus host disease in allogeneic stem cell graft recipients.

Abstract: The present invention relates generally to a cell culture process and to cells produced therefrom. More particularly, the present invention provides a method of supporting dendritic cell viability, proliferation and/or differentiation. The dendritic cells of the present invention are useful, inter alia, in the immunotherapy of cancer, infectious disease, autoimmunity and tumour therapy and as adjuvants, immune system modulating agents, immunotherapeutic agents and tolerising agents.

Abstract: The present invention discloses the genomic structure and sequence of DCAL. It also provides methods for producing a genetically modified non-human animal model having altered DCAL gene function as well as methods for using this model in the study of the immune system, and particularly DC function, and in screening for biologically active agents that modulate DCAL function. The present invention also discloses the use of such modulatory agents in methods for modulating immune responses, and in compositions for treating and/or preventing DCAL-related conditions. Also disclosed is the use of the genetically modified non-human animal model of the invention in the study of brain physiology and more particularly neuronal cell function.